Hidde Clemens Gerardus Overtoom

Dr. Hidde Clemens Gerardus Overtoom

Surgery, Amsterdam UMC, Amsterdam, Noord-Holland, The Netherlands
+2
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Annals of Surgery
Verified
Journal Article
Open access
HOHidde Clemens Gerardus Overtoom
Hidde Clemens Gerardus Overtoom
BEBen M. Eyck
Ben M. Eyck
BWBerend J. van der Wilk
Berend J. van der Wilk
BNBo J. Noordman
Bo J. Noordman
PSPieter C. van der Sluis
Pieter C. van der Sluis
OGon behalf of the SANO study group*
on behalf of the SANO study group*
Objective: To investigate whether prolonged time to surgery negatively affects survival, pathologic outcome, or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer. Background: Historically, the standard time to surgery (TTS) has been 6 to 8 weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease 6 weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity. Methods: Patients with locally advanced esophageal cancer who had biopsy-proven residual disease 6 weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS>12w vs TTS≤12w). The primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathologic outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT. Results: Forty patients were included for TTS>12w and 127 for TTS≤12w. TTS>12w was associated with better overall survival [adjusted hazard ratio (aHR) 0.46, 95% CI: 0.24–0.90], and disease-free survival (aHR 0.48, 95% CI: 0.24–0.94), but also with more postoperative respiratory complications (aOR 3.66, 95% CI: 1.52–9.59). Other outcomes were comparable between both groups. Conclusions: Prolonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.

3 May 2024 in British Journal of Surgery
Verified
Journal Article
Closed access
PDF file
XGXing Gao
Xing Gao
HOHidde Clemens Gerardus Overtoom
Hidde Clemens Gerardus Overtoom
BEBen M Eyck
Ben M Eyck
SHShi-Han Huang
Shi-Han Huang
DNDaan Nieboer
Daan Nieboer
JLJan J B van Lanschot
Jan J B van Lanschot
Locally advanced oesophageal squamous cell carcinoma can be treated with neoadjuvant chemoradiotherapy or chemotherapy followed by oesophagectomy. Discrepancies in pathological response rates have been reported between studies from Eastern versus Western countries. The aim of this study was to compare the pathological response to neoadjuvant chemoradiotherapy in Eastern versus Western countries. Databases were searched until November 2022 for studies reporting pCR rates after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma. Multi-level meta-analyses were performed to pool pCR rates separately for cohorts from studies performed in centres in the Sinosphere (East) or in Europe and the Anglosphere (West). For neoadjuvant chemoradiotherapy, 51 Eastern cohorts (5636 patients) and 20 Western cohorts (3039 patients) were included. Studies from Eastern countries included more men, younger patients, more proximal tumours, and more cT4 and cN+ disease. Patients in the West were more often treated with high-dose radiotherapy, whereas patients in the East were more often treated with a platinum + fluoropyrimidine regimen. The pooled pCR rate after neoadjuvant chemoradiotherapy was 31.7% (95% c.i. 29.5% to 34.1%) in Eastern cohorts versus 40.4% (95% c.i. 35.0% to 45.9%) in Western cohorts (fixed-effect P = 0.003). For cohorts with similar cTNM stages, pooled pCR rates for the East and the West were 32.5% and 41.9% respectively (fixed-effect P = 0.003). The pathological response to neoadjuvant chemoradiotherapy is less favourable in patients treated in Eastern countries compared with Western countries. Despite efforts to investigate accounting factors, the discrepancy in pCR rate cannot be entirely explained by differences in patient, tumour, or treatment characteristics.

26 October 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
HOHidde Clemens Gerardus Overtoom
Hidde Clemens Gerardus Overtoom
MPMark Portelli
Mark Portelli
SSSergio Sanchez-Cordero
Sergio Sanchez-Cordero
JSJada Marie Saunders
Jada Marie Saunders
NDNatalia Dowgiałło-Gornowicz
Natalia Dowgiałło-Gornowicz
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz
One of the greatest threats to public health in the 21st century is anthropogenic climate change. Healthcare services worldwide account for 4.9% of global CO2 emissions, with operating rooms being the most resource-intensive areas of the hospital. The need for environmentally sustainable change is a priority. Reliable quantitative data on emissions remain limited, which may hinder informed decision-making on surgical sustainability. The aim of this study is to develop and validate an easily accessible and user-friendly calculator to quantitatively estimate procedure-related carbon dioxide equivalent (CO2-eq) emissions of minimally invasive cholecystectomy across a range of countries, hospital volumes, and healthcare settings. The ECOMIS project follows a multiphase, stepwise design. The present study will focus on minimally invasive cholecystectomies. The calculator variables will be selected based on a systematic literature review of factors influencing CO2-eq emissions, with life cycle assessment (LCA) considered an established and comprehensive methodology for assessing CO2-eq emissions. The project will generate a comprehensive quantitative overview of the environmental impact associated with key variables involved in minimally invasive surgery. This tool has the potential to facilitate tailor-made and evidence-based decision-making and promote more sustainable surgical practices.

17 July 2026 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
HOHidde Clemens Gerardus Overtoom
Hidde Clemens Gerardus Overtoom
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz
Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ cancer in the Netherlands. Perioperative treatment strategies have evolved toward intensified systemic therapy, with perioperative chemotherapy, particularly the FLOT regimen. The preferred approach for surgical treatment of EGJ cancer remains debated, however, minimally invasive transthoracic techniques are increasingly adopted and have led to superior radicality and decreased morbidity. Centralization of care with specialized multidisciplinary teams has been consistently associated with improved surgical quality and survival in the Netherlands, as confirmed by the registry‐based nationwide quality control.

2 August 2026
Verified
Book Chapter
Closed access
PDF file
HOHidde Clemens Gerardus Overtoom
Hidde Clemens Gerardus Overtoom
SGSuzanne S. Gisbertz
Suzanne S. Gisbertz